Please provide your email address to receive an email when new articles are posted on . Phase 1 pharmacokinetics results showed comparability between SB17 and ustekinumab. Phase 3 results of SB17 will ...
Please provide your email address to receive an email when new articles are posted on . Imuldosa, an ustekinumab biosimilar, is approved for multiple inflammatory diseases, including Crohn’s disease ...
Johnson & Johnson’s second quarter earnings, released on Tuesday, largely beat analysts’ expectations, thanks in part to growth in autoimmune drugs, particularly by the Crohn’s disease medication ...
One of the up-and-coming drugs AbbVie is pinning its hopes on to make up for falling Humira sales, Skyrizi, just beat out its competitor Stelara, from Johnson & Johnson on many points in a Phase 3 ...
Approved for the same indications as the reference product, STEQEYMA will be priced with a wholesale acquisition cost (WAC) list price at an 85% discount to the current WAC list price of STELARA to ...
BAD VILBEL, Germany and REYKJAVIK, Iceland, Jan. 10, 2024 (GLOBE NEWSWIRE) -- Partners STADA and Alvotech today announced that the European Commission issued a marketing authorization for Uzpruvo® ...
After plotting a course to grow by leveraging its biosimilar expertise, Sandoz has inked a deal to get involved in one of the industry's next major biosim debuts. Monday, Sandoz said it signed a deal ...
Even as Johnson & Johnson prepares to weather the impact of negotiated Medicare drug prices on two of its top medicines, the company is aiming to change a different government pricing framework with a ...
Partners STADA and Alvotech today announced that the European Commission issued a marketing authorization for Uzpruvo® (AVT04), a biosimilar candidate to Stelara® (ustekinumab). The centralized ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results